November 12, 2026

Gene CASS4’s Role in Alzheimer’s Disease Progression

A gene associated with Alzheimer’s, known as CASS4, has been linked to vulnerabilities affecting the brain’s immune cells. This discovery provides researchers with a new potential target for therapies aimed at slowing Alzheimer’s progression, as per a recent study conducted on mice.

John Lukens, the director at the University of Virginia’s Harrison Family Translational Research Center, noted that while CASS4 had been identified as a major Alzheimer’s risk gene, its overall effect on brain health was less understood. Lukens explained, “Our work shows that CASS4 helps microglia to corral and contain neurotoxic amyloid beta aggregates. Its deletion leads to aggravated amyloid plaque spread, neuron damage, and cognitive decline.”

The Role of Microglia in Brain Health

Alzheimer’s is characterized by the buildup of sticky amyloid-beta plaques and tau protein tangles in the brain. Microglia, the brain’s immune cells, are believed to play a role in how the brain responds to such damage. They can form barriers around amyloid-beta plaques, mitigating their harm.

Lukens’ team focused on CASS4 after it emerged as an Alzheimer’s risk factor in various studies. Their findings indicate that the gene regulates microglia, enabling them to respond effectively to harmful plaques.

In mice lacking CASS4, microglia were less effective at controlling amyloid-beta spread, leading to plaque expansion, neuron damage, and cognitive decline. The disruption in CASS4 also altered gene activity, which may have implications for other neurodegenerative diseases.

Potential Treatment Approaches

The research suggests that therapies enhancing CASS4 activity in microglia could limit Alzheimer’s progression. Lukens expressed that promoting CASS4 function offers a novel strategy against the disease.

His team aims to explore whether CASS4 influences other conditions like Parkinson’s, ALS, or multiple sclerosis. Collaborations with UVA’s Manning Institute are in progress to develop CASS4-targeting drugs for future clinical trials.

Behavioral neurologist Dr. James Bateman cautioned that while findings in mice are critical, they are preliminary steps. He noted, “Preclinical findings are important but transitioning to human treatments involves a long and complex process.”

The study, led by Lukens and Addie Walsh, underscores the need for further research to understand this gene’s role in brain pathology.

Reference: Lukens, J. R., Walsh, A. E. et al. (2026). Alzheimer’s genetic risk factor CASS4 controls microglial focal adhesion biology and amyloidosis. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20260104.

TAGS: